Pneumococcal vaccination using 23-valent vaccine: clinical efficacy in urban and rural inhabitants suffering from chronic obstructive pulmonary disease

2012 ◽  
pp. 104-110 ◽  
Author(s):  
M. P. Kostinov ◽  
A. A. Ryzhov ◽  
A. V. Chebykina ◽  
N. S. Brynza ◽  
T. S. Novikova ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Efficacy ◽  
Pneumococcal Vaccination ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION WITH 13-VALENT CONJUGATE AND 23-VALENT POLYSACCHARIDE VACCINE IN PATIENTS WITH COPD

2014 ◽  
Vol 11 (4) ◽  
pp. 12-17
Author(s):  
A D PROTASOV
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Conjugate Vaccine ◽  
Clinical Efficacy ◽  
Pneumococcal Infection ◽  
Pneumococcal Vaccination ◽  
Polysaccharide Vaccine ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients

Comparative data on the clinical efficacy of vaccination in patients with chronic obstructive pulmonary disease (COPD) against pneumococcal infection using 13-valent conjugate vaccine (PCV-13) or 23-valent polysaccharide vaccine (PPV-23) is cited. Background. To evaluate a clinical efficacy (the number of exacerbations, courses of antimicrobial chemother- apy, hospitalizations) of PCV-13 and PPV-23 in patients with chronic obstructive pulmonary disease (COPD). Methods. The study involved 55 patients with COPD. Patients who met inclusion/exclusion criteria were divided in 2 groups: I group of patients received one dose of the vaccine «Prevenar-13» intramuscularly in the left shoul- der (n=32), II group received one dose of the vaccine «Pneumo-23» intramuscularly in the left shoulder (n=23). We estimated the number of exacerbations per year prior to vaccination and during the year after vaccination, the number of courses of antibiotic therapy for a year prior to vaccination and for a year after immunization, the number of hospitalizations for COPD exacerbation during the year prior to vaccination and during the year after immunization. Results. Vaccination of patients with COPD with PCV-13 or PPV-23 was characterized by the same high clinical efficacy, without the expressed benefits in favor of any drug. Conclusion. Vaccination of patients with COPD against pneumococcal infection with PCV-13 or PPV-23 is char- acterized by a high clinical efficacy. High cost of the 13-valent conjugate pneumococcal vaccine vs a polysac- charide vaccine additionally requires a proof of it’s benefit use in patients with COPD. Until such evidences and their wide representation in the scientific literature should be done vaccination of COPD patients with 13-valent conjugate vaccine is still discussable.

Improving Pneumococcal Vaccination Rates in Patients With Chronic Obstructive Pulmonary Disease

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 451A ◽  
Author(s):  
Mark C. Fok ◽  
James Lan ◽  
Heywood Choi ◽  
Gina Tsai ◽  
Benny Lau ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Pneumococcal Vaccination ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Vaccination Rates

scholarly journals A Prediction Model for Intermediate- and High-risk Pulmonary Hypertension During the Acute Exacerbation of Chronic Obstructive Pulmonary Disease

2021 ◽  
Author(s):  
Xilian Feng ◽  
Jiahua Liang ◽  
Jiamin Chen ◽  
Weiyan Chen ◽  
Hui Li ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Hypertension ◽  
High Risk ◽  
Prediction Model ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Clinical Efficacy ◽  
Chronic Obstructive ◽  
Discriminative Ability ◽  
Obstructive Pulmonary Disease

Abstract Background: Pulmonary hypertension (PH) is a serious complication of COPD and is associated with poor prognosis. There are currently no established predictive models for PH during the acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Objective: To establish a prediction model for intermediate- and high-risk PH in AECOPD patients.Methods: This study collected data from 203 AECOPD patients and divided the patients into a model group and an external validation group. The influence of each parameter on PH was analysed through univariate and multivariate analyses, and these data were used to build a prediction model. Finally, the discriminative ability, calibration ability and clinical efficacy of the model were tested.Result: Age, RDW-CV and RDW-SD were related to PH, so these variables were used to establish a prediction model. In addition, the discriminative ability, calibration ability and clinical efficacy of the model were affirmed.Conclusion: This study established a clinical prediction model for AECOPD patients with PH, and the prediction model has certain clinical value for assisting in the screening of intermediate- and high-risk patients with PH.

scholarly journals The Effect of Different Regimens of Vaccination against Pneumococcal Infection on the Clinical Course of Chronic Obstructive Pulmonary Disease: Focus on Changes in Sputum Microorganism Population

2021 ◽  
Vol 99 (7) ◽  
pp. 7-17
Author(s):  
M. P. Kostinov ◽  
А. D. Protasov ◽  
А. V. Zhetkov ◽  
M. L. Shteyner ◽  
Yu. V. Tezikov ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Pneumococcal Infection ◽  
Pneumococcal Vaccination ◽  
Statistical Processing ◽  
Clinical Effectiveness ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Microorganism Population ◽  
History Of

The objective: development of the best vaccination regimen against pneumococcal infection in patients with chronic obstructive pulmonary disease (COPD) with consideration of changes in microbiological and clinical parameters.Subjects and Methods. 115 patients with COPD were randomized into 4 pneumococcal vaccination groups, they were examined and followed up for 4 years; 112 patients completed the study complying with the protocol. Detail medical history of all subjects was collected. To verify the diagnosis of COPD, all subjects underwent external respiratory function test and bronchodilator test (salbutamol, 400 μg) according to the standard method. The classic microbiological assessment was used in this study. The clinical effectiveness of vaccination was assessed. Statistical processing of the results was performed using StatPlus Pro 6.2.0.0 software (license number 2883).Results. Сonsecutive vaccination with pneumococcal conjugate and polysaccharide vaccines leads to decreased isolation rate of pneuniococcus from the sputum of CODP patients. The frequency of exacerbations, the need for antibiotic chemotherapy and hospitalizations also goes down.

scholarly journals The Clinical Efficiency and the Mechanism of Sanzi Yangqin Decoction for Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-21
Author(s):  
Mengqi Wang ◽  
Wenwen Gu ◽  
Fuguang Kui ◽  
Fan Gao ◽  
Yuji Niu ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Molecular Docking ◽  
Pulmonary Disease ◽  
Clinical Efficacy ◽  
Network Pharmacology ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Volume Percentage ◽  
The Core

This work is carried out to evaluate the clinical efficacy of Sanzi Yangqin decoction (SZYQD) treating chronic obstructive pulmonary disease (COPD) and to analyze its mechanism. The clinical efficacy of SZYQD treating COPD was evaluated by meta-analysis, and its mechanism was analyzed by network pharmacology. Molecular docking validation of the main active compounds and the core targets was performed by AutoDock vina software. A cigarette smoke (CS) and LPS-induced COPD model in ICR mice was constructed to confirm the effects of luteolin on COPD. Results showed that SZYQD has a greater benefit on the total effect (OR = 3.85, 95% CI [3.07, 4.83], P = 1 ) in the trial group compared with the control group. The percentage of forced expiratory volume in one second (FEV1%) (MD = 0.5, 95% CI [0.41, 0.59], P < 0.00001 ) and first seconds breathing volume percentage of forced vital capacity (FEV1%/FVC) were improved (MD = 5.97, 95% CI [3.23, 8.71], P < 0.00001 ). There are 27 compounds in SZYQD targeting 104 disease targets related to COPD. PPI network analysis indicated that EGFR, MMP9, PTGS2, MMP2, APP, and ERBB2 may be the core targets for the treatment of COPD. Molecular docking demonstrated that luteolin in SZYQD showed the strongest binding activity to core targets. Experimental results revealed that the expression of COPD-related targets in lung tissue was significantly increased in the COPD group and was improved in the luteolin group. Our data indicated that SZYQD has a curative effect on COPD and luteolin is a candidate compound for COPD treatment by regulating EGFR, MMP9, PTGS2, MMP2, APP, and ERBB2.

Sign in / Sign up

Export Citation Format

Share Document